(Q39366534)

11 September 2017

(-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus (English)

1 reference

11 September 2017

1 reference

1 reference

Chao Chen

1

1 reference

11 September 2017

Hui Qiu

2

1 reference

11 September 2017

Jian Gong

3

1 reference

11 September 2017

Qing Liu

4

1 reference

11 September 2017

Han Xiao

5

1 reference

11 September 2017

Xin-Wen Chen

6

1 reference

11 September 2017

Bin-Lian Sun

7

1 reference

11 September 2017

Rong-Ge Yang

8

1 reference

11 September 2017

11 April 2012

1 reference

11 September 2017

12

1 reference

based on heuristic

inferred from page(s)

published in

Archives of Virology

1 reference

11 September 2017

157

1 reference

11 September 2017

1301-1312

1 reference

11 September 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1007/s00705-012-1304-0

11 September 2017

0 references

cites work

Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Differential in vitro cytotoxicity of (-)-epicatechin gallate (ECG) to cancer and normal cells from the human oral cavity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

A novel small molecule inhibitor of hepatitis C virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Beneficial effects of green tea--a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Inhibition of Epstein-Barr virus lytic cycle by (-)-epigallocatechin gallate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

The heat shock protein inhibitor Quercetin attenuates hepatitis C virus production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Identification of GBF1 as a Cellular Factor Required for Hepatitis C Virus RNA Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication - inducible cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Antiviral effect of epigallocatechin gallate on enterovirus 71.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Epigallocatechin gallate inactivates clinical isolates of herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

The evaluation of catechins that contain a galloyl moiety as potential HIV-1 integrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Dual function of (--)-epigallocatechin gallate (EGCG) in healthy human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Cell culture and infection system for hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Epigallocatechin gallate induces apoptosis of monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Monitoring the Antiviral Effect of Alpha Interferon on Individual Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Epigallocatechin gallate inhibits the HIV reverse transcription step

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Complete replication of hepatitis C virus in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Replication of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Telaprevir for the treatment of chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Hepatitis C treatment: current and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Induction of apoptosis by epigallocatechin-3-gallate in human lymphoblastoid B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Persistent and transient replication of full-length hepatitis C virus genomes in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

(-)-Epigallocatechin gallate inhibits hepatitis C virus (HCV) viral protein NS5B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Analysis of Hepatitis C Virus Superinfection Exclusion by Using Novel Fluorochrome Gene-Tagged Viral Genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Hepatitis C virus (HCV) NS2 protein up-regulates HCV IRES-dependent translation and down-regulates NS5B RdRp activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Global epidemiology of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Antiviral effect of catechins in green tea on influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Modulation of beta-lactam resistance in Staphylococcus aureus by catechins and gallates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Sequence diversity of hepatitis C virus: implications for immune control and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Peginterferon and ribavirin treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

A single ascending dose study of epigallocatechin gallate in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Inhibition of adenovirus infection and adenain by green tea catechins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

(-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Robust hepatitis C virus infection in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-012-1304-0

10.1007/S00705-012-1304-0

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference